Last edition
News about "platinum-based chemotherapy"
US FDA Grants Fast Track Designation to OncoC4's Cesalatamig
US FDA grants Fast Track Designation to OncoC4’s cesalatamig for patients with NSCLC whose disease has progressed following PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.
Platinum-based Chemotherapy | 17/09/2026 | By News Bureau
Novocure secures Japan insurance reimbursement for Optune Lua in advanced lung cancer treatment
Novocure receives reimbursement approval from Japan’s Ministry of Health, Labour and Welfare of Japan for Optune Lua, enabling insured access for advanced NSCLC patients using Tumour Treating Fields therapy.
Platinum-based Chemotherapy | 05/03/2026 | By News Bureau | 238
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy